Yeah. Thank you, Gary. A couple of things in the Specialty Generics that I would highlight, one is, if you look at the release this morning on oxycodone, you see that we have 34% growth. As we move forward into future quarters we’re going to be anniversarying some of the benefits that we put in place this time last year. So the percentage growth in the future quarters will likely be slower. Hydrocodone, I would say just was exceptionally strong in the second quarter and there has been a resetting of the market if you will that we saw in the last few months as competitors were kind of readjusting internally for Schedule II, and we see that smoothing out in future quarters. Methylphenidate ER, I think we’ve been very clear to say we plan to continue shipping it, but it’s certainly, with the BX rating is below where we were this time last year, albeit we always assume we’re going to have competition in the marketplace, so we’re not surprised with where Methylphenidate ER is playing out. In the other controlled substances line, you’ll see that it’s up about 9%, and that really is the authorized generic on EXALGO that’s the only real thing that’s driving that particular line item. And then you’ll see in the other category, a 90% increase in the release and most of that is driven by BioVectra, which is what Mark mentioned earlier as it relates to Acthar, BioVectra had a very strong quarter that we do not expect to repeat. And that was the lion share of that increase. So that’s really what’s going on in Specialty Generics. And with regards to your question about future price increases, Garry, I think that there’s always opportunities for us to take price across a pretty broad spectrum of controlled substances. The way I think about it is, we’ve taken now some significant pricing actions in a couple of the major categories that Matt described. Future price increases will be more opportunistic in nature, and that’s one of the very good things about being a broad supplier across 43 different categories in controlled substances. You can take full advantage of opportunities when they come up to take price, but on a go forward basis, more than like you’re going to see the price increases be more muted overall and more opportunistic. Thanks, Garry. Next question please.